Prospective Evaluation of the StatusFirst™ CHF NT-proBNP Device in Human Whole Blood and Plasma Samples

Completed

Conditions studied: Congestive Heart Failure (CHF)

In brief

The primary objective of the study is to establish the correlation between NT-proBNP measurements in fresh human whole blood samples and those in plasma samples from the same study subjects, where said samples are collected in EDTA and Li-Hep anticoagulant tubes and measured by the StatusFirst™ CHF NT-proBNP device in conjunction with the DXpressTM Reader in a laboratory setting.

Key facts

Study ID

NCT00734045

Run by

Nanogen, Inc.

People needed

450

Starts

2008-02-01

Expected to finish

2008-11-01

Last updated by the study team

2008-12-10

Who can join

Age: 45 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Have clinically confirmed heart failure (NYHA class I-IV) or have presented to an emergency room or clinic with signs, symptoms and/or risk factors suggestive of heart failure, OR
• Be non-CHF controls greater than 45 years of age with no history of heart failure or cardiovascular disease.

You may not qualify if…

• Be 45 years of age or younger

Where it is running

• US Department of Veteran's Affairs — San Diego, California, United States
• San Francisco General Hospital — San Francisco, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.